Residual disease-guided strategy combining ibrutinib and venetoclax for the treatment of relapsed or refractory chronic lymphocytic leukemia

被引：0
|
作者：
Stocker, Nicolas
机构：
来源：
HEMATOLOGIE | 2022年 / 28卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：174 / 175
页数：2
相关论文
共 50 条
  • [31] Successful treatment of relapsed chronic lymphocytic leukemia with venetoclax in a patient with severe chronic kidney disease
    Sugiura, Hiroyuki
    Sezaki, Nobuo
    Ishikawa, Tatsunori
    Kuroi, Taiga
    Okamoto, Sachiyo
    Nomura, Naho
    Masunari, Taro
    Nakasako, Yukio
    Kiguchi, Toru
    Tanimoto, Mitsune
    CLINICAL CASE REPORTS, 2022, 10 (04):
  • [32] Cost Effectiveness of Zanubrutinib Versus Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia
    Kang, Dong-Won
    Wang, Li
    Short, Nicholas J.
    Ferrajoli, Alessandra
    Wang, Yucai
    Zhou, Shouhao
    Shen, Chan
    PHARMACOECONOMICS, 2024, 42 (04) : 409 - 418
  • [33] Cost Effectiveness of Zanubrutinib Versus Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia
    Dong-Won Kang
    Li Wang
    Nicholas J. Short
    Alessandra Ferrajoli
    Yucai Wang
    Shouhao Zhou
    Chan Shen
    PharmacoEconomics, 2024, 42 : 409 - 418
  • [34] Comparison of Venetoclax Based Treatments for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia
    Heyman, Benjamin M.
    Choi, Michael Y.
    Kipps, Thomas J.
    BLOOD, 2023, 142
  • [35] Ibrutinib in Relapsed Chronic Lymphocytic Leukemia REPLY
    Byrd, John C.
    O'Brien, Susan
    James, Danelle F.
    NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (13): : 1278 - 1279
  • [36] Combined Ibrutinib and Venetoclax for Patients With Chronic Lymphocytic Leukemia
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (02) : 16 - 17
  • [37] Undetectable minimal residual disease should be the goal of venetoclax therapy in relapsed and refractory chronic lymphocytic leukaemia
    Lew, Thomas
    Anderson, Mary Ann
    Lin, Victor
    Handunnetti, Sasanka
    Came, Neil
    Westerman, David
    Meaghan, Wall
    Tam, Constantine
    Roberts, Andrew W.
    Seymour, John F.
    LEUKEMIA & LYMPHOMA, 2020, 61 : 172 - 174
  • [38] ALPINE: zanubrutinib versus ibrutinib in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma
    Hillmen, Peter
    Brown, Jennifer R.
    Eichhorst, Barbara F.
    Lamanna, Nicole
    O'Brien, Susan M.
    Qiu, Lugui
    Salmi, Tommi
    Hilger, James
    Wu, Kenneth
    Cohen, Aileen
    Huang, Jane
    Tam, Constantine S.
    FUTURE ONCOLOGY, 2020, 16 (10) : 517 - 523
  • [39] Risk Model for Overall Survival for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Validated for Patients on Ibrutinib, Idelalisib, Venetoclax, or Chemoimmuniotheraphy
    Soumerai, Jacob D.
    Ni, Ai
    Darif, Mohamed
    Londhe, Anil
    Xing, Guan
    Mun, Yong
    Kay, Neil E.
    Shanafelt, Tait D.
    Chaffee, Kari G.
    Furman, Richard R.
    Hillmen, Peter
    Sharman, Jeff
    Seymour, John F.
    Chanan-Khan, Asher A.
    Byrd, John C.
    Jones, Jeffrey A.
    Ferrante, Lucille A.
    Dreiling, Lyndah K.
    Mobasher, Mehrdad
    Stark, Thomas
    Reddy, Vijay
    Howes, Angela J.
    James, Danelle
    Bhargava, Pankaj
    Zelenetz, Andrew D.
    BLOOD, 2018, 132
  • [40] COST-MINIMIZATION OF VENETOCLAX WITH RITUXIMAB VERSUS IBRUTINIB IN RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA IN THE BRAZILIAN PRIVATE HEALTHCARE SYSTEM
    Brito Filho, C.
    Vitale, V.
    Vieira, F. M.
    VALUE IN HEALTH, 2019, 22 : S483 - S483
12345